Does a long-acting formulation of the integrase inhibitor raltegravir protect humanized BLT mice from repeated high-dose vaginal HIV challenges?
These preclinical results demonstrated the efficacy of long-acting raltegravir in preventing vaginal HIV transmission.
This facile and convenient system should allow production of retroviral vectors encoding potentially toxic proteins, cell cycle inhibitors or inducers of apoptosis, all of which would interfere with vector production if expressed in the retroviral packaging cell.